ReviewDrug design, development and therapy2014
Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?
Review in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- A meta-analysis of montelukast for recurrent wheeze in preschool children.European journal of pediatrics · 2017Pooled it
- Pharmacokinetics and Bioequivalence Evaluation of Two Montelukast Sodium Chewable Tablets in Healthy Chinese Volunteers Under Fasted and Fed Conditions.Drug design, development and therapy · 2021Trial
- Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.The European respiratory journal · 2019Trial
- Comparative analysis of adverse drug reaction reports for leukotriene receptor antagonists mainly indicated for allergic rhinitis and asthma: a WHO VigiAccess study.Frontiers in medicine · 2026Article
- Targeted biologic therapies and advanced drug delivery approaches in asthma management: a clinical perspective.Inflammopharmacology · 2025Review
- The effects of montelukast sodium in conjunction with budesonide/formoterol on pulmonary function and serum markers (interleukin-6, tumor necrosis factor-α, eosinophils (EOS) count) in obstructive airway diseases (asthma and chronic obstructive pulmonary disease).Postepy dermatologii i alergologii · 2025Article
- Effect of leukotriene receptor antagonist use on the future risk of Parkinson's disease in older patients with asthma.Brain communications · 2025Article
- β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk.Annals of neurology · 2023Article
- Adverse Drug Reactions (ADRs) of Montelukast in Children.Children (Basel, Switzerland) · 2022Article
- Increased Risk of Tourette Syndrome with Leukotriene Modifier Use in Children with Allergic Diseases and Asthma: A Nationwide Population-Based Study.Children (Basel, Switzerland) · 2022Article
- Article
- PGC-1α activity and mitochondrial dysfunction in preterm infants.Frontiers in physiology · 2022Review
- Prescription Patterns of Asthma Preventers Among Children and Adolescents Between Australia and South Korea.Frontiers in pharmacology · 2022Article
- Treatment of pediatric mild persistent asthma with low-dose budesonide inhalation suspension vs. montelukast in China.World journal of pediatrics : WJP · 2021Article
- Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines.Journal of asthma and allergy · 2021Review
- The Role of Innate Immunity and Bioactive Lipid Mediators in COVID-19 and Influenza.Frontiers in physiology · 2021Review
- Article
- CB2 Agonist (AM1241) Improving Effect on Ovalbumin-Induced Asthma in Rats.Iranian journal of pharmaceutical research : IJPR · 2020Article
- Prevalence of Montelukast Use as an Add-On Therapy among Iraqi Asthmatics on Treatment Attending Al-Kindy Teaching Hospital and Al-Zahraa Center of Asthma and Allergy.Open access Macedonian journal of medical sciences · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a common childhood atopic disease associated with chronicity and impaired quality of life. As there is no cure for this disease, treatment relies on avoidance of triggers such as food and aeroallergens, the use of inhaled bronchodilators/corticosteroids and antiallergic or immunomodulating therapies. Inhaled corticosteroids (ICSs) and bronchodilators have been the mainstay. However, in Asia, myths and fallacies regarding Western medicine and corticosteroids are prevalent and lead to nonadherence to treatment. Also, use of traditional and proprietary herbal medicines is popular. In the past decades, a novel class of nonsteroidal immunomodulating montelukasts has become available. This article reviews the evidence for the effectiveness and clinical efficacy of these medications. A number of randomized and controlled trials have been performed over the years. The majority of studies confirm the usefulness of montelukast as monotherapy and add-on therapy to ICS in mild to moderate childhood asthma across all age groups. ICSs are generally superior to montelukasts for asthma management. However, montelukast has a place in the treatment of young children with viral-triggered wheezing diseases, exercise-induced asthma, and in children whose parents are steroid-phobic and find ICS unacceptable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.